Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis by 송정식 et al.
RESEARCH ARTICLE Open Access
Non-histologic factors discriminating
proliferative lupus nephritis from
membranous lupus nephritis
Oh Chan Kwon1, Jung Hwan Park1, Hyeong-Cheon Park2, Seung Min Jung1, Sang-Won Lee1, Jason Jungsik Song1,
Yong-Beom Park1 and Min-Chan Park1*
Abstract
Background: To investigate non-histologic factors that can discriminate proliferative lupus nephritis (LN) from
membranous LN in patients with systemic lupus erythematosus with renal manifestations.
Methods: Patients with biopsy-proven proliferative LN (class III ± V and class IV ± V) and membranous LN (class V) were
included. Non-histologic factors were compared between the two groups. A logistic regression analysis was performed to
identify the factors associated with proliferative LN. To assess the accuracy of these factors in discriminating between
proliferative LN and membranous LN, we performed a receiver-operating characteristic analysis.
Results: Of the total 168 patients with biopsy-proven LN, 150 patients (89.3%) had proliferative LN, and 18 patients
(10.7%) had membranous LN. In the multivariable logistic regression analysis, positive anti-double-stranded DNA (anti-
dsDNA) antibody (adjusted OR = 11.200, 95% CI = 2.202–56.957, p = 0.004) was associated with proliferative LN, while
positive anti-U1RNP antibody (adjusted OR = 0.176, 95% CI = 0.040–0.769, p= 0.021) and higher glomerular filtration rate
(GFR) (adjusted OR = 0.973, 95% CI = 0.951–0.994, p= 0.013) were inversely associated with proliferative LN. Among these
covariates, the anti-dsDNA antibody (area under the curve = 0.806, 95% CI = 0.695–0.916) had the highest accuracy in
discriminating between proliferative LN and membranous LN.
Conclusion: The positivity of anti-dsDNA antibody was associated with proliferative LN, while the positivity of anti-U1RNP
antibody and GFR were inversely associated with proliferative LN. The anti-dsDNA antibody had a good accuracy in
discriminating proliferative LN from membranous LN.
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Background
Lupus nephritis (LN) is one of the common manifestations
of systemic lupus erythematosus (SLE) that causes signifi-
cant morbidity and mortality [1]. According to the Inter-
national Society of Nephrology/Renal Pathology Society
2003 classification, LN is classified into six classes according
to the glomerular pathology [2]. Among these classes, class
III, class IV, and class V have the potential to cause long-
term renal damage [3]. Class III and class IV (proliferative
LN) are highly inflammatory with immune complex depos-
ition in the subendothelial space, whereas class V (mem-
branous LN) is less inflammatory with immune complex
deposition in the subepithelial space [2]. Proliferative LN is
usually treated with potent immunosuppressive agents,
whereas membranous LN may be managed conservatively
with antiproteinuric agents if patients have subnephrotic
proteinuria or with immunosuppressive agents if patients
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have nephrotic-range proteinuria [4, 5]. The risk of progres-
sion to end-stage renal disease (ESRD) differs between pro-
liferative LN and membranous LN, with proliferative LN
having a worse prognosis (risk of ESRD, 10–20% for prolif-
erative LN vs < 10% for membranous LN) [4, 6]. Consider-
ing the differences in the treatment strategy and renal
prognosis between proliferative LN and membranous LN,
it is important to distinguish one from the other.
The confirmative modality for diagnosing LN and dis-
tinguishing proliferative LN from membranous LN is
renal biopsy [5]. The American College of Rheumatology
(ACR) recommends renal biopsies in patients with SLE
who have increasing serum creatinine levels of an un-
known cause, proteinuria at protein levels of ≥ 1 g per
day (either in a 24-h urine specimen or on a spot pro-
tein/creatinine ratio [PCR]), or a combination of the fol-
lowing: proteinuria at protein levels of ≥ 0.5 g per day
plus ≥ 5 red blood cells (RBCs) per high power field
(HPF) or proteinuria at protein levels of ≥ 0.5 g per day
plus cellular casts [7]. Although it is apparently import-
ant to perform renal biopsies to confirm the diagnosis of
LN and to guide appropriate therapeutic decision-
making based on the classification of LN, there are some
circumstances where renal biopsies are difficult to per-
form, such as in patients under mechanical ventilation
who have difficulty in assuming the prone position, pa-
tients with uncorrectable bleeding diathesis, and patients
with small kidney sizes. Given that renal biopsies may
not always be available, it is clinically meaningful to
identify non-histologic factors that can discriminate pro-
liferative LN from membranous LN.
To date, data regarding clinical factors predictive of pro-
liferative LN are limited. In this study, we aimed to iden-
tify non-histologic factors predictive of proliferative LN.
Materials and methods
Patients
Data from two independent LN cohorts from two ter-
tiary referral hospitals in Seoul, Korea, were retrospect-
ively reviewed. Both cohorts consisted of patients
diagnosed with LN via renal biopsy between July 2006
and December 2018. All patients met the 1997 ACR
classification criteria for SLE [8]. Renal biopsies were
performed in accordance with the indications recom-
mended by the ACR [7]. The patients were categorized
into the proliferative LN (class III, class IV, class III + V
and class IV + V) and membranous LN (class V) groups
based on their renal biopsy reports. Given that the thera-
peutic strategy is similar between pure proliferative LN
(class III and class IV) and mixed proliferative LN (class
III + V and class IV + V), and that the therapeutic strat-
egy in both is different from that in membranous LN [7,
9], pure proliferative LN (class III and class IV) and
mixed proliferative LN (class III + V and class IV + V)
were both categorized as proliferative LN in the primary
analysis. As the purpose of this study was to identify the
factors that discriminate proliferative LN from mem-
branous LN, patients with class I, class II, and class VI
were excluded. This study was approved by the Institu-
tional Review Board (IRB) of Gangnam Severance Hos-
pital (IRB No: 3-2019-0072). Owing to the retrospective
nature of this study, the requirement for informed con-
sent was waived.
Covariates
Data on the following covariates at the time of renal biopsy
were collected: age, sex, presence of hypertension and dia-
betes mellitus, manifestations of SLE other than those of
LN, positivity of antibodies (Abs) to extractable nuclear an-
tigens, anti-double-stranded DNA (anti-dsDNA) Ab, lupus
anticoagulant, anti-β2 glycoprotein Ab and anti-cardiolipin
Ab, C3 and C4 levels, serum albumin and creatinine levels,
glomerular filtration rate (GFR), urine PCR, urinalysis
results, and SLE Disease Activity Index 2000 (SLE-
DAI-2 K) [10]. Autoantibodies were measured using
an automated fluoroimmunoassay analyzer (EliA; Phadia,
Uppsala, Sweden). Lupus anticoagulants were assessed
using the IL Test TM LAC Screen/Confirm Kit (Instru-
mentation Laboratory Co., Bedford, MA, USA).
Statistical analysis
The patients’ characteristics were summarized using de-
scriptive statistics. To compare the characteristics be-
tween the proliferative LN group and membranous LN
group, Student’s t test or Mann-Whitney test was used
for continuous variables and Fisher’s exact test or chi-
square test (when appropriate) for categorical variables.
Multivariable logistic regression models were con-
structed to identify the covariates associated with prolif-
erative LN. Covariates with a p value of < 0.05 in the
univariable logistic regression analysis were incorporated to
the multivariable models. In the multivariable analysis, the
variable inflation factor was tested to exclude multicolli-
nearity among covariates. The Hosmer-Lemeshow test was
used to assess the goodness of fit for the logistic regression
models. Antibodies and complements (C3 and C4) were
analyzed as binary variables (positive/negative for anti-
bodies, and low/not low for complements) in univariable
analysis and multivariable analysis (model 1) and were ana-
lyzed as continuous variables in multivariable analysis
(model 2). We used a receiver-operating characteristic
(ROC) analysis to assess the ability of the covariates identi-
fied in the multivariable models in discriminating prolifera-
tive LN from membranous LN. ROC curves were
generated, and the associated area under the curve (AUC)
for each covariate was determined. The statistical signifi-
cance level was set at a p value of < 0.05. All analyses were
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conducted using the SPSS software (version 25.0; IBM Cor-
poration, Armonk, NY, USA).
Sensitivity analysis
To test the robustness of our results, we performed sev-
eral sensitivity analyses. First, we used a more restrictive
definition of proliferative LN. Instead of including both
pure proliferative LN (class III and class IV) and mixed
proliferative LN (class III + V and class IV + V) in the
proliferative LN group, we included only the pure prolif-
erative LN (class III and class IV) in the proliferative LN
group and performed multivariable logistic regression
analysis and ROC analysis. Second, we compared mixed
proliferative LN (class III + V and class IV + V) with
membranous LN (class V). Third, as patients with clas-
ses I, II, and VI would also have to undergo a renal bi-
opsy for diagnostic purposes, we included the patients
with classes I, II, and VI and compared pure proliferative
LN (class III and class IV) with non-proliferative LN
(class I, class II, class V, and class VI).
Results
Patient characteristics
A total of 176 patients with biopsy-proven LN were in-
cluded. The patients were predominantly women
(90.9%), with a mean age of 36.7 ± 15.0 years. Among the
patients, 150 patients (85.2%) had proliferative LN, and
18 patients (10.2%) had membranous LN. Of the 150 pa-
tients with proliferative LN, 122 (81.3%) patients had
pure proliferative LN (class III, 38 patients; class IV, 84
patients) and 28 (18.7%) patients had mixed proliferative
LN (class III + V, 17 patients; class IV + V, 11 patients)
(Table 1). Three (1.7%) patients with class I, four (2.3%)
patients with class II, and one (0.6%) patient with class
VI were excluded for primary analysis.
The comparison of the characteristics between the two
groups is shown in Table 2. Age (p = 0.269), sex distribu-
tion (p = 0.649), and the proportion of patients with
hypertension (p > 0.999) and diabetes mellitus (p = 0.599)
did not differ between the two groups. The proportion of
patients with mucocutaneous manifestations (p > 0.999),
musculoskeletal manifestations (p = 0.408), neuropsychi-
atric manifestations (p = 0.149), and serositis (p = 0.475)
was similar in the two groups; conversely, hematologic
manifestations were more common in the patients with
proliferative LN (44.7% vs 16.7%, p = 0.023). In the com-
parison of serologic covariates, no significant differences
were observed in the positivity for anti-Sm Ab (p = 0.384),
anti-Ro Ab (p = 0.885), anti-La Ab (p = 0.258), lupus anti-
coagulant (p = 0.768), anti-β2 glycoprotein Ab (p = 0.077),
and anti-cardiolipin Ab (p = 0.566) and albumin levels
(p = 0.800). The patients with proliferative LN were less
commonly positive for anti-U1RNP Ab (48.7% vs 77.8%,
p = 0.020) and more commonly positive for anti-dsDNA
Ab (88.0% vs 50.0%, p < 0.001), and more commonly had
low C3 (94.0% vs 61.1%, p < 0.001) and low C4 (79.3% vs
50.0%, p = 0.015), higher creatinine level (1.13 ± 0.79mg/
dL vs 0.70 ± 0.26mg/dL, p < 0.001), and lower GFR
(83.2 ± 37.0mL/min/1.73m2 vs 105.1 ± 23.8mL/min/1.73
m2, p = 0.002). Regarding the urine laboratory data, the
urine PCR (p = 0.778) and proportion of patients with py-
uria (p = 0.053) and urine casts (p = 0.202) did not differ
between the two groups. The proportion of patients with
urine RBC of ≥ 5/HPF was higher in the proliferative LN
group (72.7% vs 38.9%, p = 0.003). The SLEDAI-2 K was
also higher in the proliferative LN group (17.1 ± 5.8 vs
12.2 ± 5.8, p = 0.001).
Covariates associated with proliferative LN
In the univariable logistic regression analysis, the pres-
ence of hematologic manifestations (unadjusted odds ra-
tio [OR] = 4.036, 95% confidence interval [CI] = 1.121–
14.527, p = 0.033), positive anti-dsDNA Ab (unadjusted
OR = 7.333, 95% CI = 2.574–20.893, p < 0.001), low C3
(unadjusted OR = 9.970, 95% CI 3.117–31.891, p <
0.001), low C4 (unadjusted OR 3.839, 95% CI 1.405–
10.486, p = 0.009), creatinine levels (unadjusted OR =
10.645, 95% CI = 1.350–83.953, p = 0.025), presence of
urine RBC of ≥ 5/HPF (unadjusted OR = 4.718, 95%
CI = 1.516–11.509, p = 0.006), and higher SLEDAI-2 K
(unadjusted OR = 1.173, 95% CI = 1.063–1.294, p =
0.001) were associated with proliferative LN. The posi-
tivity of anti-U1RNP Ab (unadjusted OR = 0.271, 95%
CI = 0.085–0.861, p = 0.027) and GFR (unadjusted
OR = 0.980, 95% CI = 0.964–0.997, p = 0.021) were in-
versely associated with proliferative LN. These covari-
ates were included in the multivariable models, except
for the creatinine level, because of the multicollinear-
ity with the GFR.
Table 1 Histologic characteristics of the 176 patients
N = 176
ISN/RPS class
I, n (%) 3 (1.7%)
II, n (%) 4 (2.3%)
III, n (%) 38 (21.6%)
IV, n (%) 84 (47.7%)
III + V, n (%) 17 (9.7%)
IV + V, n (%) 11 (6.3%)
V, n (%) 18 (10.2%)
VI, n (%) 1 (0.6%)
Activity index, median (IQR) 7.0 (3.0–11.0)
Chronicity index median (IQR) 1.0 (0.5–2.5)
ISN/RPS International Society of Nephrology/Renal Pathology Society, IQR
interquartile range
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In multivariable analysis model 1, anti-U1RNP (posi-
tive/negative), anti-dsDNA Ab (positive/negative), C3
(low/not low), and C4 (low/not low) were analyzed as
the categorical variables. An alternative multivariable
analysis model (model 2) was also performed, in which
anti-U1RNP, anti-dsDNA Ab, C3 level, and C4 level
were analyzed as the continuous variables. Both the posi-
tivity (model 1) for and level (model 2) of anti-dsDNA Ab
(model 1: adjusted OR = 11.200, 95% CI = 2.202–56.957,
p = 0.004; model 2: adjusted OR = 1.008, 95% CI = 1.002–
1.014, p = 0.014) were associated with proliferative LN;
conversely, both the positivity (model 1) for and level
Table 2 Comparison of the clinical characteristics between the patients with proliferative LN and membranous LN
Proliferative LN (N = 150) Membranous LN (N = 18) p
Age, mean (± SD), years 35.8 (± 14.3) 39.8 (± 15.4) 0.269
Female sex, n (%) 138 (92.0%) 16 (88.9%) 0.649
Hypertension, n (%) 34 (22.7%) 4 (22.2%) > 0.999
Diabetes mellitus, n (%) 9 (6.0%) 0 (0.0%) 0.599
SLE manifestations
Mucocutaneous, n (%) 41 (27.3%) 5 (27.8%) > 0.999
Musculoskeletal, n (%) 41 (27.3%) 3 (16.7%) 0.408
Neuropsychiatric, n (%) 10 (6.7%) 3 (16.7%) 0.149
Serositis, n (%) 23 (15.3%) 1 (5.6%) 0.475
Hematologic, n (%) 67 (44.7%) 3 (16.7%) 0.023
Serology
Positive anti-Sm Ab, n (%) 59 (39.3%) 9 (50.0%) 0.384
Positive anti-Ro Ab, n (%) 89 (59.3%) 11 (61.1%) 0.885
Positive anti-La Ab, n (%) 44 (29.3%) 3 (16.7%) 0.258
Positive anti-U1RNP Ab, n (%) 73 (48.7%) 14 (77.8%) 0.020
Positive anti-dsDNA Ab, n (%) 132 (88.0%) 9 (50.0%) < 0.001
Anti-dsDNA Ab level, median (IQR), IU/mL 230.3 (79.0–380.0) 9.0 (2.5–123.5) < 0.001
Positive anti-dsDNA Ab and negative anti-U1RNP Ab, n (%) 66 (44.0%) 1 (5.6%) 0.002
Positive anti-U1RNP Ab and negative anti-dsDNA Ab, n (%) 7 (4.7%) 6 (33.3%) 0.001
Positive anti-dsDNA Ab and anti-U1RNP Ab, n (%) 66 (44.0%) 8 (44.4%) 0.971
Positive lupus anticoagulant, n (%) 32 (21.3%) 3 (16.7%) 0.768
Positive anti-β2 glycoprotein I Ab, n (%) 18 (12.0%) 5 (27.8%) 0.077
Positive anti-cardiolipin Ab, n (%) 39 (26.0%) 3 (16.7%) 0.566
Low C3, n (%) 141 (94.0%) 11 (61.1%) < 0.001
C3 level, median (IQR), mg/dL 41.0 (27.9–60.1) 64.7 (44.3–92.3) 0.001
Low C4, n (%) 119 (79.3%) 9 (50.0%) 0.015
C4 level, median (IQR), mg/dL 5.5 (2.5–11.9) 12.8 (7.3–23.5) < 0.001
Albumin level, mean (± SD), g/dL 2.8 (± 0.7) 2.9 (± 0.9) 0.800
Creatinine level, mean (± SD), mg/dL 1.13 (± 0.79) 0.70 (± 0.26) < 0.001
GFR, mean (± SD), mL/min/1.73 m2 83.2 (± 37.0) 105.1 (± 23.8) 0.002
Urine
Urine PCR, median (IQR), mg/g 3935.0 (1903.4–6439.7) 3464.5 (2061.8–5775.0) 0.778
Urine RBC of ≥ 5/HPF, n (%) 109 (72.7%) 7 (38.9%) 0.003
Urine WBC of ≥ 5/HPF, n (%) 86 (57.3%) 6 (33.3%) 0.053
Urine cast, n (%) 31 (20.7%) 1 (5.6%) 0.202
SLEDAI-2K, mean (± SD) 17.1 (± 5.8) 12.2 (± 5.8) 0.001
LN lupus nephritis, SLE systemic lupus erythematosus, Ab antibody, anti-dsDNA anti-double-stranded DNA, GFR glomerular filtration rate, PCR protein/creatinine
ratio, RBC red blood cell, HPF high power field, WBC white blood cell, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000, SD standard deviation,
IQR interquartile range
Kwon et al. Arthritis Research & Therapy          (2020) 22:138 Page 4 of 12
(model 2) of anti-U1RNP Ab (model 1: adjusted OR =
0.176, 95% CI = 0.040–0.769, p = 0.021; model 2: adjusted
OR = 0.985, 95% CI = 0.0976–0.994, p = 0.002) were in-
versely associated with proliferative LN. Higher GFR
(model 1: adjusted OR = 0.973, 95% CI = 0.951–0.994, p =
0.013; model 2: adjusted OR = 0.969, 95% CI = 0.946–
0.994, p = 0.014) was also inversely associated with prolif-
erative LN (Table 3).
Ability of the covariates in discriminating proliferative LN
The ROC curves for anti-U1RNP Ab, anti-dsDNA Ab,
and the GFR are shown in Fig. 1. Anti-dsDNA Ab had
the highest discrimination ability (AUC = 0.806, 95%
CI = 0.695–0.916), followed by anti-U1RNP Ab (AUC =
0.677, 95% CI = 0.527–0.827) and GFR (AUC = 0.662,
95% CI = 0.554–0.770). When a combination of anti-
dsDNA Ab, anti-U1RNP Ab, and GFR was used as a
composite parameter, the discrimination ability (AUC =
0.864, 95% CI = 0.792–0.937) was higher than when each
parameter was used as a single parameter (Fig. 1d).
Sensitivity analysis
When using the stricter proliferative LN definition (i.e.,
pure proliferative LN: class III and class IV), the ORs of
anti-dsDNA Ab (model 1: adjusted OR = 19.591, 95%
CI = 2.518–152.431, p = 0.004; model 2: adjusted OR =
1.008, 95% CI = 1.002–1.015, p = 0.012), anti-U1RNP Ab
(model 1: adjusted OR = 0.178, 95% CI = 0.034–0.922,
p = 0.040; model 2: adjusted OR = 0.987, 95% CI =
0.978–0.996, p = 0.007), and GFR (model 1: adjusted
Table 3 Factors associated with proliferative LN
Univariable analysis Multivariable analysis (model 1) Multivariable analysis (model 2)
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age 0.982 (0.951–1.014) 0.269
Female sex 1.437 (0.295–7.006) 0.653
Hypertension 1.026 (0.317–3.322) 0.966
Diabetes mellitus N/A 0.999
Mucocutaneous manifestations 0.978 (0.328–2.915) 0.968
Musculoskeletal manifestations 1.881 (0.517–6.836) 0.337
Neuropsychiatric manifestations 0.357 (0.088–1.442) 0.148
Serositis 3.079 (0.390–24.280) 0.286
Hematologic manifestations 4.036 (1.121–14.527) 0.033 3.277 (0.665–16.148) 0.145 1.963 (0.393–9.810) 0.411
Positive anti-Sm Ab 0.648 (0.243–1.728) 0.386
Positive anti-Ro Ab 0.928 (0.341–2.529) 0.885
Positive anti-La Ab 2.075 (0.572–7.528) 0.267
Positive anti-U1RNP Aba 0.271 (0.085–0.861) 0.027 0.176 (0.040–0.769) 0.021 0.985 (0.976–0.994) 0.002
Positive anti-dsDNA Aba 7.333 (2.574–20.893) < 0.001 11.200 (2.202–56.957) 0.004 1.008 (1.002–1.014) 0.014
Positive lupus anticoagulant 1.356 (0.370–4.974) 0.646
Positive anti-β2 glycoprotein I Ab 0.355 (0.113–1.112) 0.075
Positive anti-cardiolipin Ab 1.757 (0.483–6.396) 0.393
Low C3a 9.970 (3.117–31.891) < 0.001 1.886 (0.255–13.932) 0.534 1.012 (0.968–1.058) 0.608
Low C4a 3.839 (1.405–10.486) 0.009 1.224 (0.229–6.552) 0.813 0.929 (0.834–1.033) 0.175
Albumin level 0.886 (0.434–1.805) 0.738
Creatinine level 10.645 (1.350–83.953) 0.025
GFR 0.980 (0.964–0.997) 0.021 0.973 (0.951–0.994) 0.013 0.969 (0.946–0.994) 0.014
Urine PCR 1.000 (0.987–1.013) 0.986
Urine RBC of ≥ 5/HPF 4.178 (1.516–11.509) 0.006 2.053 (0.426–9.893) 0.370 1.721 (0.307–9.652) 0.537
Urine WBC of ≥ 5/HPF 2.687 (0.958–7.543) 0.060
Urine cast 4.429 (0.567–34.578) 0.156
SLEDAI-2K 1.173 (1.063–1.294) 0.001 1.046 (0.900–1.216) 0.557 1.112 (0.923–1.338) 0.263
Ab antibody, anti-dsDNA anti-double-stranded DNA, GFR glomerular filtration rate, PCR protein/creatinine ratio, RBC red blood cell, HPF high power field, WBC
white blood cell, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000, OR odds ratio, CI confidence interval, N/A not applicable
aAnalyzed as binary variables (anti-U1RNP Ab, positive/negative; anti-dsDNA Ab, positive/negative; C3, low/not low; C4, low/not low) in univariable analysis and
multivariable analysis (model 1) and analyzed as continuous variables in multivariable analysis (model 2)
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OR = 0.966, 95% CI = 0.941–0.992, p = 0.010; model 2:
adjusted OR = 0.967, 95% CI = 0.942–0.992, p = 0.011)
remained significant (Table 4). Further, the discrimin-
ation ability of anti-U1RNP Ab (AUC = 0.673, 95%
CI = 0.522–0.823), anti-dsDNA Ab (AUC = 0.822, 95%
CI = 0.713–0.931), GFR (AUC = 0.688, 95% CI = 0.579–
0.798), and combination of anti-dsDNA Ab, anti-
U1RNP Ab, and GFR as a composite parameter
(AUC = 0.873, 95% CI = 0.801–0.945) was similar to
the primary analysis (Fig. 2).
In another sensitivity analysis where mixed prolifera-
tive LN (class III + V and IV + V) was compared with
membranous LN (class V), positivity of anti-dsDNA Ab
was still significantly associated with mixed proliferative
LN (model 1: adjusted OR = 4.545, 95% CI 1.107–18.661,
p = 0.036) (Table 5), although the effect size was attenu-
ated compared with the primary analysis (anti-dsDNA
Ab in model 1: adjusted OR = 11.200) (Table 3) and in
the sensitivity analysis where pure proliferative LN was
compared with membranous LN (anti-dsDNA Ab in
Fig. 1 Receiver-operating characteristic curves for the predictive value of a anti-U1RNP Ab, b anti-dsDNA Ab, c GFR, and d combination of anti-
U1RNP Ab, anti-dsDNA Ab, and GFR as a composite parameter, for predicting proliferative LN (class III, class IV, class III + V, and class IV + V). Ab,
antibody; anti-dsDNA, anti-double-stranded DNA; GFR, glomerular filtration rate; LN, lupus nephritis; AUC, area under the curve; CI,
confidence interval
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model 1: adjusted OR = 19.591) (Table 4). The effect size
of anti-U1RNP Ab (unadjusted OR = 0.286, 95% CI
0.075–1.086, p = 0.066) and GFR (unadjusted OR =
0.988, 95% CI 0.968–1.009, p = 0.273) was also attenu-
ated and failed to reach statistical significance (Table 5).
In comparison between pure proliferative LN (class III
and class IV) and non-proliferative LN (class I, class II, class
V, and class VI), anti-dsDNA Ab (model 1: adjusted OR=
13.741, 95% CI = 3.058–61.753, p = 0.001; model 2: adjusted
OR= 1.008, 95% CI = 1.003–1.012, p = 0.002) was associ-
ated with pure proliferative LN, and anti-U1RNP Ab
(model 1: adjusted OR = 0.273, 95% CI = 0.085–0.873, p =
0.029; model 2: adjusted OR = 0.991, 95% CI = 0.984–0.998,
p = 0.012) and GFR (model 1: adjusted OR= 0.970, 95%
CI = 0.952–0.989, p = 0.003; model 2: adjusted OR = 0.972,
95% CI = 0.954–0.990, p = 0.002) were inversely associated
with pure proliferative LN, supporting their value in pre-
dicting proliferative LN (Table 6).
Discussion
In this retrospective cohort study, we showed that the
positivity for and level of anti-dsDNA Ab were signifi-
cantly associated with proliferative LN and that the posi-
tivity for and level of anti-U1RNP Ab and the GFR were
inversely associated with proliferative LN. Among these
covariates, anti-dsDNA Ab had the highest ability to dis-
criminate proliferative LN from membranous LN. These
findings are meaningful in that they may aid in thera-
peutic decision-making for clinicians when renal biop-
sies are difficult to perform.
Table 4 Sensitivity analysis: factors associated with pure proliferative LN
Univariable analysis Multivariable analysis (model 1) Multivariable analysis (model 2)
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age 0.985 (0.954–1.017) 0.351
Female sex 1.400 (0.281–6.976) 0.681
Hypertension 1.043 (0.318–3.422) 0.945
Diabetes mellitus N/A 0.999
Mucocutaneous manifestations 1.046 (0.347–3.153) 0.936
Musculoskeletal manifestations 1.932 (0.526–7.097) 0.321
Neuropsychiatric manifestations 0.304 (0.071–1.305) 0.109
Serositis 3.535 (0.446–28.035) 0.232
Hematologic manifestations 4.531 (1.248–16.453) 0.022 4.997 (0.819–30.479) 0.081 2.150 (0.408–11.333) 0.367
Positive anti-Sm Ab 0.718 (0.267–1.936) 0.513
Positive anti-Ro Ab 1.051(0.381–2.904) 0.923
Positive anti-La Ab 2.262 (0.618–8.279) 0.218
Positive anti-U1RNP Aba 0.268 (0.083–0.859) 0.027 0.178 (0.034–0.922) 0.040 0.987 (0.978–0.996) 0.007
Positive anti-dsDNA Aba 8.385 (2.824–24.896) < 0.001 19.591 (2.518–152.431) 0.004 1.008 (1.002–1.015) 0.012
Positive lupus anticoagulant 1.224 (0.328–4.572) 0.763
Positive anti-β2 glycoprotein I Ab 0.337 (0.104–1.088) 0.069
Positive anti-cardiolipin Ab 1.854 (0.504–6.819) 0.353
Low C3a 14.891 (4.044–54.831) < 0.001 2.216 (0.216–22.738) 0.503 1.004 (0.959–1.052) 0.866
Low C4a 5.421 (1.906–15.422) 0.002 1.763 (0.313–9.916) 0.520 0.947 (0.839–1.069) 0.376
Albumin level 0.898 (0.420–1.918) 0.781
Creatinine level 11.857 (1.524–92.273) 0.018
GFR 0.978 (0.961–0.995) 0.012 0.966 (0.941–0.992) 0.010 0.967 (0.942–0.992) 0.011
Urine PCR 0.999 (0.986–1.013) 0.934
Urine RBC of ≥ 5/HPF 4.238 (1.515–11.852) 0.006 1.803 (0.358–9.087) 0.475 1.724 (0.299–9.952) 0.542
Urine WBC of ≥ 5/HPF 2.604 (0.917–7.391) 0.072
Urine cast 4.381 (0.556–34.519) 0.161
SLEDAI-2K 1.181 (1.067–1.308) 0.001 1.026 (0.884–1.190) 0.739 1.094 (0.899–1.330) 0.370
Ab antibody, anti-dsDNA anti-double-stranded DNA, GFR glomerular filtration rate, PCR protein/creatinine ratio, RBC red blood cell, HPF high power field, WBC
white blood cell, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000, OR odds ratio, CI confidence interval, N/A, not applicable
aAnalyzed as binary variables (anti-U1RNP Ab, positive/negative; anti-dsDNA Ab, positive/negative; C3, low/not low; C4, low/not low) in univariable analysis and
multivariable analysis (model 1) and analyzed as continuous variables in multivariable analysis (model 2)
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Several previous studies have reported non-histologic
factors associated with LN in patients with SLE [11–14].
Although there are some inconsistencies among these re-
ports, anti-dsDNA Ab is consistently reported as an auto-
antibody that is associated with the occurrence of renal
disease in SLE [11–14]. Mechanistically, anti-dsDNA Ab
is involved in the development of LN by binding to glom-
erular and tubulointerstitial cells, inducing cell prolifera-
tion, inflammation, apoptosis, and fibrosis [15]. Similar to
our present finding, a previous study also reported anti-
dsDNA Ab as an important factor associated with
proliferative LN compared with non-proliferative LN [16].
We further advanced the previous report by performing
ROC analysis and providing the predictive value of anti-
dsDNA Ab. Moreover, we also included anti-ENA Abs
such as anti-Ro Ab, anti-La Ab, and anti-U1RNP Ab as
variables in our analysis and found that anti-U1RNP Ab
was inversely associated with proliferative LN, which was
not reported in the previous study.
Anti-U1RNP Ab, which is by definition found in 100%
of patients with mixed connective tissue disease, is found
in 20–40% of patients with SLE [17]. Previous studies
Fig. 2 Receiver-operating characteristic curves for the predictive value of a anti-U1RNP Ab, b anti-dsDNA Ab, c GFR, and d combination of anti-
U1RNP Ab, anti-dsDNA Ab, and GFR as a composite parameter, for predicting pure proliferative LN (class III and class IV). Ab, antibody; anti-
dsDNA, anti-double-stranded DNA; GFR, glomerular filtration rate; LN, lupus nephritis; AUC, area under the curve; CI, confidence interval
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have reported an association between anti-U1RNP Ab
and occurrence of pulmonary hypertension in patients
with SLE [18–20]. There are conflicting data regarding
the association between anti-U1RNP Ab and renal dis-
ease in SLE [11–13, 21]. One study reported a 66% re-
duced risk of LN development in patients with SLE with
positive anti-U1RNP Ab findings [21], whereas other
studies reported no association between the presence of
anti-U1RNP Ab and LN development [11, 12] or even a
higher risk of LN development [13]. Although the asso-
ciation between anti-U1RNP Ab and the presence of
renal disease in SLE is controversial, the presence of
anti-U1RNP Ab may have clinical significance when
confined to patients with LN in that it is inversely asso-
ciated with proliferative LN. In other words, the pres-
ence of anti-U1RNP Ab in patients with LN may suggest
that the glomerular pathology might be membranous
LN. This finding is meaningful because it is the first to
indicate an association between anti-U1RNP Ab and the
renal pathologic class.
We also found that the GFR was inversely associated
with proliferative LN; a lower GFR was suggestive of pro-
liferative LN. The other covariates associated with renal
manifestations, such as amount of proteinuria and pres-
ence of hematuria, pyuria, and urine casts, were not asso-
ciated with proliferative LN. Although these covariates are
Table 5 Sensitivity analysis: factors associated with mixed proliferative LN (classes III + V and IV + V, n = 28) vs membranous LN
(class V, n = 18)
Univariable analysis Multivariable analysis (model 1) Multivariable analysis (model 2)
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age 0.965 (0.920–1.012) 0.142
Female sex 1.625 (0.208–12.705) 0.644
Hypertension 0.955 (0.228–3.995) 0.949
Diabetes mellitus N/A > 0.999
Mucocutaneous manifestations 0.709 (0.180–2.792) 0.623
Musculoskeletal manifestations 1.667 (0.370–7.515) 0.506
Neuropsychiatric manifestations 0.600 (0.107–3.363) 0.561
Serositis 1.308 (0.110–15.570) 0.832
Hematologic manifestations 2.368 (0.544–10.317) 0.251
Positive anti-Sm Ab 0.400 (0.116–1.376) 0.146
Positive anti-Ro Ab 0.552 (0.165–1.838) 0.333
Positive anti-La Ab 1.364 (0.294–6.319) 0.692
Positive anti-U1RNP Aba 0.286 (0.075–1.086) 0.066
Positive anti-dsDNA Abb 4.600 (1.207–17.524) 0.025 4.545 (1.107–18.661) 0.036 1.003 (0.999–1.007) 0.159
Positive lupus anticoagulant 2.000 (0.452–8.841) 0.361
Positive anti-β2 glycoprotein I Ab 0.433 (0.099–1.900) 0.267
Positive anti-cardiolipin Ab 1.364 (0.294–6.319) 0.692
Low C3a 3.818 (0.922–15.808) 0.065
Low C4a 1.333 (0.406–4.379) 0.635
Albumin level 0.866 (0.435–1.721) 0.680
Creatinine level 5.076 (0.446–57.756) 0.190
GFR 0.988 (0.968–1.009) 0.273
Urine PCR 1.002 (0.985–1.020) 0.808
Urine RBC of ≥ 5/HPF 3.929 (1.122–13.755) 0.032 3.326 (0.559–19.795) 0.187 2.402 (0.464–12.428) 0.296
Urine WBC of ≥ 5/HPF 3.091 (0.895–10.672) 0.074
Urine cast 4.636 (0.509–42.246) 0.174
SLEDAI-2K 1.134 (1.015–1.266) 0.026 1.020 (0.872–1.195) 0.801 1.074 (0.935–1.233) 0.315
Ab antibody, anti-dsDNA anti-double-stranded DNA, GFR glomerular filtration rate, PCR protein/creatinine ratio, RBC red blood cell, HPF high power field, WBC
white blood cell, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000, OR odds ratio, CI confidence interval, N/A not applicable
aAnalyzed as binary variables (anti-U1RNP Ab, positive/negative; C3, low/not low; C4, low/not low) in univariable analysis
bAnalyzed as binary variables (Anti-dsDNA Ab, positive/negative) in univariable analysis and multivariable analysis (model 1) and analyzed as continuous variables
in multivariable analysis (model 2)
Kwon et al. Arthritis Research & Therapy          (2020) 22:138 Page 9 of 12
the components used in measuring disease activity (SLE-
DAI-2 K), they are not necessarily associated with a par-
ticular renal histology. Rather, the GFR was closely
associated with the histologic classes of LN, although it is
not a component of the SLEDAI-2 K.
Sensitivity analyses showed that effect sizes (i.e., ORs) of
anti-dsDNA Ab, anti-U1RNP Ab, and GFR were greatest
when pure proliferative LN was compared with membran-
ous LN, followed by when proliferative LN (both pure and
mixed proliferative LN) was compared with membranous
LN, and when mixed proliferative LN was compared with
membranous LN. This suggests that anti-dsDNA Ab,
anti-U1RNP Ab, and GFR are particularly useful in detect-
ing pure proliferative LN. Further, in the analysis where
class I, class II, and class VI were included, anti-dsDNA
Ab, anti-U1RNP Ab, and GFR were still significantly asso-
ciated with pure proliferative LN, showing the robustness
of the findings of the primary analysis.
We used the ROC analysis to assess the ability of anti-
U1RNP Ab, anti-dsDNA Ab, and the GFR to predict
proliferative LN. Given that the AUCs can be interpreted
as follows: 1.00–0.90 = excellent, 0.80–0.90 = good, 0.70–
0.80 = fair, 0.60–0.70 = poor, and 0.50–0.60 = fail [22],
anti-dsDNA Ab (AUC = 0.806) had good accuracy, while
anti-U1RNP Ab (AUC = 0.677) and the GFR (AUC =
0.662) had poor accuracy in discriminating between pro-
liferative LN and membranous LN in the present study.
When anti-dsDNA Ab was combined with anti-U1RNP
Table 6 Sensitivity analysis: factors associated with pure proliferative LN (classes III and IV, n = 122) vs non-proliferative LN (classes I,
II, V and VI, n = 26)
Univariable analysis Multivariable analysis (model 1) Multivariable analysis (model 2)
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age 0.977 (0.951–1.002) 0.074
Female sex 2.036 (0.586–7.082) 0.263
Hypertension 0.809 (0.308–2.120) 0.666
Diabetes mellitus N/A 0.999
Mucocutaneous manifestations 1.690 (0.591–4.834) 0.328
Musculoskeletal manifestations 1.623 (0.566–4.649) 0.367
Neuropsychiatric manifestations 0.335 (0.090–1.241) 0.102
Serositis 2.495 (0.547–11.375) 0.238
Hematologic manifestations 2.460 (0.964–6.276) 0.060
Positive anti-Sm Ab 0.838 (0.358–1.962) 0.684
Positive anti-Ro Ab 1.212 (0.513–2.863) 0.662
Positive anti-La Ab 2.488 (0.802–7.719) 0.115
Positive anti-U1RNP Aba 0.345 (0.135–0.880) 0.026 0.273 (0.085–0.873) 0.029 0.991 (0.984–0.998) 0.012
Positive anti-dsDNA Aba 8.385 (3.210–21.900) < 0.001 13.741 (3.058–61.753) 0.001 1.008 (1.003–1.012) 0.002
Positive lupus anticoagulant 1.347 (0.424–4.276) 0.613
Positive anti-β2 glycoprotein I Ab 0.544 (0.177–1.674) 0.289
Positive anti-cardiolipin Ab 2.039 (0.654–6.362) 0.220
Low C3a 10.400 (3.062–35.318) < 0.001 2.072 (0.281–15.292) 0.475 0.994 (0.958–1.031) 0.747
Low C4a 3.975 (1.586–9.967) 0.003 1.811 (0.430–7.635) 0.418 0.958 (0.868–1.058) 0.395
Albumin level 0.665 (0.347–1.274) 0.218
Creatinine level 2.722 (0.970–7.634) 0.057
GFR 0.983 (0.969–0.996) 0.013 0.970 (0.952–0.989) 0.003 0.972 (0.954–0.990) 0.002
Urine PCR 1.003 (0.990–1.015) 0.669
Urine RBC of ≥ 5/HPF 3.678 (1.534–8.819) 0.004 2.038 (0.538–7.720) 0.295 2.400 (0.588–9.796) 0.222
Urine WBC of ≥ 5/HPF 2.083 (0.875–4.959) 0.097
Urine cast 1.976 (0.549–7.113) 0.297
SLEDAI-2K 1.149 (1.056–1.251) 0.001 1.012 (0.896–1.144) 0.845 1.017 (0.883–1.171) 0.818
Ab antibody, anti-dsDNA anti-double-stranded DNA, GFR glomerular filtration rate, PCR protein/creatinine ratio, RBC red blood cell, HPF high power field, WBC
white blood cell, SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000, OR odds ratio, CI confidence interval, N/A not applicable
aAnalyzed as binary variables (anti-U1RNP Ab, positive/negative; anti-dsDNA Ab, positive/negative; C3, low/not low; C4, low/not low) in univariable analysis and
multivariable analysis (model 1) and analyzed as continuous variables in multivariable analysis (model 2)
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Ab and GFR, the accuracy was numerically higher
(AUC = 0.864) than when used as a single parameter.
Similar results were also found in our sensitivity analysis.
None of the covariates had an AUC of 1.00; therefore,
these covariates cannot completely replace renal biopsy
findings in discriminating between proliferative LN and
membranous LN. However, in circumstances where
renal biopsy is difficult to perform, anti-dsDNA Ab or
its combination with anti-U1RNP Ab and GFR may be
useful in discriminating between them, considering its
good discriminating accuracy.
The present study has some limitations. First, as renal
biopsies were performed only in the patients with overt
clinical renal manifestations, patients with “silent” LN,
which is defined as histologic LN in the absence of clin-
ical renal manifestations [23, 24], were not included in
our study. Therefore, our findings may not be general-
ized to patients with silent LN. However, considering
that the value of renal biopsy and need for treatment is
uncertain in silent LN [23], the covariates associated
with proliferative LN in the patients with overt renal
manifestations that we identified in this study still have
clinical significance. Second, although we identified the
covariates associated with proliferative LN, explanation
for their associations cannot be drawn from the present
study data. Further studies elucidating the mechanisms
underlying these associations would be helpful. Third,
the course of the study was long, and due to the retro-
spective nature of our study, we were unable to clarify
whether the assay for measuring anti-dsDNA Ab has
changed over time. Although the unit of anti-dsDNA Ab
was the same (IU/ml) in all patients included, the poten-
tial of confounding remains by the possibility that the
assay may have changed during the study period.
Conclusion
In conclusion, we found that anti-U1RNP Ab, anti-
dsDNA Ab, and the GFR are associated with glomerular
pathology in patients with LN. Among these covariates,
the anti-dsDNA Ab had a good accuracy in discriminat-
ing proliferative LN from membranous LN. Although
anti-dsDNA Ab cannot replace the performance of renal
biopsy findings, it can be helpful in patients with SLE
with clinically overt renal manifestations who cannot
undergo renal biopsies.
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